Newly approved or newly labeled by the US Food and Drug Administration (FDA), 2012–2013
FDA Approvals
Ado-trastuzumab emtansine (Kadcyla)—for the treatment of HER2-positive, metastatic breast cancer.
Axitinib (Inlyta)—for the treatment of advanced renal cell carcinoma.
Bosutinib (Bosulif)—for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia.
Cabozantinib (Cometriq)—for the treatment of metastatic medullary thyroid cancer.
Carfilzomib (Kyprolis)—for the treatment of multiple myeloma.
Cetuximab (Erbitux)—for the treatment of KRAS mutation–negative, EGFR-expressing metastatic colorectal cancer.
Enzalutamide (Xtandi)—for the treatment of metastatic castration-resistant prostate cancer.
Everolimus (Afinitor)—for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women.
Omacetaxine mepesuccinate (Synribo)—for the treatment of chronic myeloid leukemia.
Paclitaxel (Abraxane)—for the treatment of locally advanced or metastatic non–small-cell lung cancer.
Pazopanib (Votrient)—for the treatment of soft-tissue sarcoma.
Pemetrexed (Alimta)—for the treatment of metastatic, non-squamous, non–small-cell lung cancer.
Pertuzumab (Perjeta)—for the treatment of HER2-positive, metastatic breast cancer.
Pomalidomide (Pomalyst)—for the treatment of patients with multiple myeloma.
Ponatinib (Iclusig)—for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia.
Regorafenib (Stivarga)—for the treatment of metastatic colorectal cancer.
Vincristine sulfate (Marqibo)—for the treatment of Philadelphia chromosome–negative acute lymphoblastic leukemia.
Vismodegib (Erivedge) for the treatment of metastatic basal cell carcinoma.
Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
For additional information and an up-to-date listing of newly approved oncology drugs, visit the FDA’s website.
